ARTELO BIOSCIENCES, INC.
Artelo Biosciences is a clinical-stage biopharmaceutical company based in San Diego County, California. It develops therapeutics that target lipid-signaling pathways, including the endocannabinoid system, for patients with unmet healthcare needs. Its pipeline includes ART27.13, a synthetic dual cannabinoid receptor agonist in clinical development for cancer-related anorexia; ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 in clinical development, initially targeting chemotherapy-induced peripheral neuropathy; and ART12.11, a preclinical cannabidiol and tetramethylpyrazine cocrystal being developed for anxiety, depression, PTSD and other potential indications. Artelo makes money through development and commercialization of pharmaceutical products, which it intends to provide by prescription or physician order after obtaining marketing authorization. It holds worldwide exclusive licenses for ART27.13 and its fatty acid binding protein inhibitor platform, while ART12.11 is wholly owned.
No SEC Form 4 filings for $ARTL in the last 30 days.
See all $ARTL insider activity →Artelo Biosciences reported no revenue for 3Q 2026, with a net loss of $1.77M, improved from $3.12M last year. Operating expenses fell $1.3M, driven by lower R&D and administrative costs. Diluted EPS was ($3.19), improved from ($88.8). The company's pipeline includes trials for ART27.13 and ART26.12.
Artelo Biosciences (ARTL) will report Q3'26 earnings on November 17. Analysts expect 0 USD revenue and a loss of 7.02 USD per share. Details are available on the company's financials page.
Artelo Biosciences (ARTL) presented nonclinical data on ART27.13 for chemotherapy-induced pain at a conference. The drug reduced pain symptoms in animal studies. ART27.13 is in Phase 2 trials for cancer-related weight loss, with interim data showing weight gain in patients. The company also studies it for glaucoma. ART27.13 was initially developed by AstraZeneca.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARTL (ARTELO BIOSCIENCES, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent ARTL coverage spans technology, earnings and corporate actions.
Loss narrowing may reduce downside pressure but remains a loss; limited immediate catalyst.
Weak forecast suggests likely share price decline.
Preclinical pain data and added pain endpoints in the ongoing CAReS Phase 2 study could modestly improve perceived clinical translation for ART27.13, supporting sentiment but not changing near-term fundamentals.
Potential delisting risk may pressure the stock unless compliance is achieved.
Potential delisting pressure could weigh on ARTL share price.
AlphAI scores every news story that mentions ARTL with an AI model for sentiment and relevance, and aggregates insider trades from ARTELO BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artelo Biosciences reported no revenue for 3Q 2026, with a net loss of $1.77M, improved from $3.12M last year. Operating expenses fell $1.3M, driven by lower R&D and administrative costs. Diluted EPS was ($3.19), improved from ($88.8). The company's pipeline includes trials for ART27.13 and ART26.12.
Artelo Biosciences (ARTL) will report Q3'26 earnings on November 17. Analysts expect 0 USD revenue and a loss of 7.02 USD per share. Details are available on the company's financials page.
Artelo Biosciences (ARTL) presented nonclinical data on ART27.13 for chemotherapy-induced pain at a conference. The drug reduced pain symptoms in animal studies. ART27.13 is in Phase 2 trials for cancer-related weight loss, with interim data showing weight gain in patients. The company also studies it for glaucoma. ART27.13 was initially developed by AstraZeneca.
Artelo Biosciences (ARTL) was flagged for falling below Nasdaq's $5M minimum value listing standard (MVLS) and is exploring options to regain compliance, such as capital raises or expense management. The SEC proposed a rule change, with comments due Oct 29, 2026, but final timing and terms remain uncertain.
ARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On July 22, 2026, the Securities and Exchange Commission (the “SEC”) approved The Nasdaq Stock Market LLC’s (“Nasdaq”) new listing compliance rule that requires listed companies to maintain a market value of listed securities (“MVLS”) of at least $5,000,00
Artelo Biosciences (ARTL) shares rose 193.98% after filing a patent for ART27.13, a drug candidate for obesity. Preclinical data showed 20% weight loss as monotherapy and 40% in combination with semaglutide. CEO Gregory Gorgas noted unexpected findings, including increased bone mineral density.
Artelo Biosciences (ARTL) filed a provisional patent for ART27.13, showing 20% weight loss as monotherapy and 40% with semaglutide in obese mice. The study also found improved glucose tolerance and bone density. The company aims to expand ART27.13's use in obesity, a market projected to reach $200B by 2030.
Artelo Biosciences (ARTL) reported that its drug ART27.13 achieved 20% weight loss in obese mice, matching semaglutide's results. Combined with semaglutide, weight loss doubled to 40%. ART27.13 showed no effect in lean mice, suggesting potential as an obesity treatment. The company plans to explore partnerships based on these findings.
Artelo Biosciences (ARTL) announced a 1-for-9 reverse stock split, effective August 31, 2026. The split aims to increase the stock's price and improve marketability. Post-split, there will be approximately 547,774 shares outstanding. Shareholder ownership percentages remain unchanged.
Artelo Biosciences (ARTL) said it enrolled the first patient in its Phase 2 DREAM trial of ART27.13, an oral once-daily cannabinoid-receptor agonist for glaucoma or ocular hypertension. The company expects interim results later this year. ART27.13 was originally developed by AstraZeneca and is also in a Phase 2 CAReS trial. ARTL last traded at $0.72.
